A mutated form of the huntingtin protein disrupts the normal movement of vesicles holding HT and Rab4. This leads to defects in synapses, resulting in movement abnormalities and lifespan decreases in fruit fly larvae. Findings suggest Rab4 could be a novel therapeutic target for the early intervention of Huntington's disease, before the neuronal loss and behavioral deficits associated with the neurodegenerative disorder.
Researchers discover a three molecule complex could be a target for treating Huntington's Disease, a genetic and currently incurable brain disease which causes movement disorders and dementia.
Researchers have developed a new way in which to measure the shape of the huntingtin protein in living cells.
Researchers have identified several new biological markers to measure the progression of the inherited neurodegenerative disorder Huntington's disease.
A new light-based technique for measuring levels of the toxic protein that causes Huntington's disease (HD) has been used to demonstrate that the protein builds up gradually in blood cells.
Researchers use a novel co-culturing method to create functional circuits that model Huntington's disease and find new clues to potential treatment approaches.
Synthesizing a human embryo from stem cells and using gene editing to insert the Huntingtin gene, researchers found the mutation affected the size of germ layers compared to the control embryos. Findings suggest Huntington's disease may be a neurodevelopmental disorder that presents as a neurodegenerative disease later
Researchers report huntingtin plays a critical role in long-term memory.
A new study points to a functional connection between mTOR and huntingtin.
‘HD in a dish’ will facilitate search for elusive treatment. An international consortium of Huntington’s disease experts, including several from...